

Impact of left ventricular ejection fraction and atrial fibrillation on Baroreflex Activation Therapy

Results from the BeAT-HF Study

Presenter: Michael R. Zile, MD

**Charles Ezra Daniel Professor of Medicine, Medical University of South Carolina
Chief, Division of Cardiology, RHJ Department of Veterans Affairs MC
Charleston, South Carolina, USA**

Co-Authors:

William T. Abraham, MD, The Ohio State University

Fred A. Weaver, MD, University of Southern California

Faiez Zannad, MD, Inserm Centre d'Investigation

Elizabeth Galle, MPH, CVRx Inc.

Tyson Rogers, MS, NAMSA Inc.

JoAnn Lindenfeld, MD, Vanderbilt Heart and Vascular Institute

Presenter Disclosure Information

I will discuss research examining the development of new therapies in my presentation.

I have financial relationships to disclose:

Employee of:

Department of Veterans Affairs, Medical University of SC

Consultant for:




Abbott, Boston Scientific, Corvia, CVRx, Cyclorion, EBR, Endotronics, Eli Lilly, Janssen, Medtronic, Merck, Myokardia, Novartis, ReCor, V Wave

Stockholder in: N/A

Research support from:

NHLBI, VA, DOD, CVRx, Medtronic, Novartis

BeAT-HF Top-Line Results




Atrial Fibrillation Distribution

Variable	N (%)
No AF	169 (64%)
Paroxysmal	63 (24%)
Permanent	8 (3%)
Persistent	22 (8%)
Unknown	2 (1%)

Ejection Fraction Distribution


Variable	N (%)
EF 35-25%	201 (76%)
EF < 25%	63 (24%)

Outcomes by Baseline AF Status



There were no significant interaction P-values for AF vs no AF for any parameter measured, all > 0.05

Outcomes by Baseline EF Status



There were no significant interaction P-values for EF 35-25% vs <25% for any parameter measured, all > 0.05

Outcomes by Baseline EF and AF Status

6M Improvement BAT vs Control	History of AF	No History of AF
LVEF 25– 35%	BAT N=28 Control N=46	BAT N=62 Control N=51
6MHW (meters)	59*	51*
MLWHF (points)	-12*	-15*
NYHA(% improved)	30%*	37%*
NT-proBNP (% Reduction)	-11%	-24%
LVEF < 25%	BAT N=5 Control N=8	BAT N=25 Control N=20
6MHW (meters)	127*	76*
MLWHF (points)	-16*	-15*
NYHA(% improved)	10%	38%*
NT-proBNP (% Reduction)	-64%*	-27%

* p<0.05

Conclusions

- BAT significantly improved patient-centered symptomatic endpoints
 - quality of life score
 - exercise capacity, and
 - functional status.
- These results were supported by objective evidence of significant reduction of NT-proBNP.
- BAT is equally safe and effective in patients with or without Atrial Fibrillation.
- BAT is equally safe and effective in patients with ejection fraction 35-25% or < 25%.